The high expression of CCN2(/CTGF)x in CMS4 colorectal cancer and its established role in tissue fibrosis warrant further investigation to establish the possible value of xCCN2(/CTGF) as a marker and potential therapeutic target in CRC, especially in the aggressive mesenchymal subtype. This evidence concerns the gene CCN2 and colorectal carcinoma.